83 completed, 31 unknown, 27 terminated, 18 recruiting. 94 Phase 2, 42 Phase 3, 33 Phase 1, 9 Phase 4, 2 Not applicable.
Follow Imatinib: new trials by email Literature Review of Imatinib trials Research Report on Imatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| Tofacitinib Plus Imatinib in Moderate-to-Severe Palmoplantar Pustulosis Tofacitinib, Imatinib, tofacitinib Placebo - Palmoplantar Pustulosis (PPP) | Phase 3 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 135 | 2026-08-01 | 2026-08-03 |
| A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline) Velzatinib, Imatinib - Gastrointestinal Stromal Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 800 | 2026-07-27 | 2026-10-05 |
| Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor Imatinib, Fampridine - Gastrointestinal Stromal Tumors | Phase 1 | Recruiting | University of California, San Diego | 18 | 2026-05-13 | 2026-05-27 |
| Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML Asciminib add-on, Imatinib, Dasatinib - Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia | Phase 2 | Not yet recruiting | The University of Hong Kong | 45 | 2026-03-30 | 2026-03-25 |
| Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM) Imatimib Mesylate, Placebo - Lymphangioleiomyomatosis (LAM), Lymphangioleiomyomatosis | Phase 1 | Recruiting | Columbia University | 20 | 2025-10-20 | 2026-01-21 |
| Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy Imatinib, Artesunate - Chronic Myeloid Leukemia (CML) | Phase 2 | Active not recruiting | Obafemi Awolowo University | 75 | 2025-07-01 | 2026-10-14 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-21 |
| Imatinib and Trametinib for KRAS-mutated Solid Tumor Imatinib, Trametinib - Solid Tumor Cancer | Phase 1 | Recruiting | China Medical University Hospital | 10 | 2025-05-10 | 2025-05-08 |
| Precision Cancer Therapy in Rare Cancers Imatinib, Trametinib, Dabrafenib - Rare Malignant Neoplasm | Phase 2 | Recruiting | Oslo University Hospital | 96 | 2025-03-20 | 2025-03-26 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 200 | 2025-01-01 | 2024-11-18 |
| Investigation of Novel and Established Therapies in a Human Intravenous Lipopolysaccharide Model of Sepsis Imatinib, Compound sodium lactate solution - Sepsis, Fluid Overload | Phase 1 / Phase 2 | Unknown | Belfast Health and Social Care Trust | 65 | 2024-12-01 | 2024-10-04 |
| Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease Rovadicitinib, Imatinib, Methotrexate - Graft-versus-host Disease | Phase 3 | Recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 182 | 2024-11-20 | 2025-12-08 |
| Imatinib TDM in GIST Imatinib - Gastrointestinal Stromal Tumors | Phase 2 | Recruiting | Reema A. Patel | 28 | 2024-03-26 | 2026-08-31 |
| Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL Vincristine, Dexamethasone, Imatinib - Lymphoblastic Leukemia, Philadelphia-Positive ALL | Not yet recruiting | PETHEMA Foundation | 150 | 2023-12-25 | 2023-12-19 | |
| Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency TruSight Oncology, imatinib - Inherited Bone Marrow Failure Syndrome, Familial Platelet Disorder With Predisposition to Myeloid Malignancies | Phase 1 | Recruiting | National Cancer Institute (NCI) | 71 | 2023-12-19 | 2026-10-20 |
| Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML Asciminib, Imatinib - Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive | Phase 3 | Terminated | Sarit Assouline | 8 | 2023-11-01 | 2026-05-29 |
| Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT Imatinib, Ponatinib, Blinatumomab - Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Goethe University | 220 | 2023-07-14 | 2025-04-29 |
| Pilot Study of Imatinib Cetuximab Combo for H & N Cancer Cetuximab, Imatinib - Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck | Early Phase 1 | Completed | University of Wisconsin, Madison | 15 | 2023-04-18 | 2026-10-01 |
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-07-06 |
Showing 20 of 179. Sign in to see all of them.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (56) · Leukemia (20) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (16) · Gastrointestinal Stromal Tumors (15) · Leukemia, Myeloid, Chronic-Phase (15) · Leukemia, Myeloid (7) · Philadelphia Chromosome (7) · COVID-19 (6) · Hematologic Neoplasms (5) · Melanoma (5) · Neoplasm Metastasis (5) · Bone Marrow Diseases (4) · Bronchiolitis Obliterans Syndrome (4) · Lung Neoplasms (4) · Blast Crisis (3)
M.D. Anderson Cancer Center (18) · Novartis Pharmaceuticals (18) · Bristol-Myers Squibb (7) · Gruppo Italiano Malattie EMatologiche dell'Adulto (4) · Novartis (3) · Pfizer (3) · SCRI Development Innovations, LLC (3) · Samsung Medical Center (3) · University of California, San Francisco (3) · Asan Medical Center (2) · Dana-Farber Cancer Institute (2) · Goethe University (2) · Hikma Pharmaceuticals LLC (2) · Il-Yang Pharm. Co., Ltd. (2) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (2)
United States (71) · Italy (30) · China (28) · France (27) · Germany (26) · South Korea (25) · United Kingdom (24) · Spain (23) · Canada (22) · Australia (17) · Belgium (16) · Finland (14) · Japan (14) · Netherlands (14) · Austria (13)
Anne S. Tsao, MD (3) · Jorge E Cortes, MD (2) · Jorge E. Cortes, MD (2) · Michele Baccarani (2) · Abdallah Abbadi, Professor (1) · Allen Eng Juh Yeoh, MBBS (1) · Allen Yeoh, MBBS (1) · Amir Fathi, MD (1) · Amy D Klion, M.D. (1) · Anna Turkina, Professor (1) · Anne Hansen Ree, Prof. MD PhD (1)
PMID 35235189, PMID 37553873, PMID 15315963, PMID 16344315, PMID 16565971, PMID 17213285, PMID 17709602, PMID 17805064, PMID 18223280, PMID 18272024, PMID 18728664, PMID 19735261, PMID 19933079, PMID 20145273, PMID 20385986, PMID 20525993, PMID 20525995, PMID 20572041, PMID 21467546, PMID 21769849, PMID 21828142, PMID 21856226, PMID 22160483, PMID 22198309, PMID 22207416, PMID 22453568, PMID 22511495, PMID 22645182, PMID 22825216, PMID 22949154, PMID 23109697, PMID 23116602, PMID 23328954, PMID 23380743, PMID 23403476, PMID 23502220, PMID 23678005, PMID 24140183, PMID 24311723, PMID 24335106, PMID 24357015, PMID 24472814, PMID 24532039, PMID 24919837, PMID 24944159, PMID 24948656, PMID 25007944, PMID 25082346, PMID 25086465, PMID 25609545
2023 (4), 2008 (2), 2009 (2), 2014 (2), 2017 (2), 2015 (1), 2016 (1), 2018 (1), 2019 (1), 2025 (1), P30CA016672 (1), R01CA262292 (1), R01GM036780 (1), U10CA180886 (1), U10CA180888 (1)